Ascentage Pharma to Present New Clinical Data at the ASH 2018 Annual Meeting

On November 21, 2018 Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies for the treatment of cancers, hepatitis B and aging-related diseases, reported that the Company will present clinical data of its novel BCR-ABL inhibitor HQP1351 in the upcoming 60th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Ascentage Pharma, NOV 21, 2018, View Source [SID1234531554]). The principal investigator of the study, Qian Jiang, MD, Deputy Director of Peking University People’s Hospital, Peking University Institute of Hematology, and Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, will give an oral report during the meeting. HQP1351 is a third-generation BCR-ABL inhibitor for the treatment of drug-resistant CML (Chronic Myeloid Leukemia).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Report
Topic: Safety and Efficacy of HQP1351, a Third-Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor – Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
Number: 791
Speaker: Qian Jiang, MD
Time: Monday, December 3, 2018: 3:45 PM
Location: 6E (San Diego Convention Center)
Preview Link: View Source

About HQP1351
HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral high-efficiency third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. Phase I clinical trials for patients with imatinib-resistant CML have been completed and Phase II clinical trials have been initiated.